James Richard Eshleman, Jr, M.D., Ph.D.

https://www.hopkinsmedicine.org/profiles/results/directory/profile/0011316/james-eshleman

The patient squeezes the pump to initiate pleural fluid drainage to the bag hair loss cure 9090 discount dutasteride 0.5 mg otc, the flow of which is aided by gravity hair loss 19 year old male dutasteride 0.5 mg order on line. Multiple large case series23­25 and a collective review26 demonstrated 90% of patients experienced symptomatic relief and required no further intervention hair loss 5 weeks pregnant dutasteride 0.5 mg buy on-line. Our personal experience is that the majority of patients rely on visiting nurses to perform drainage and catheter maintenance at home hair loss cure at home discount 0.5 mg dutasteride otc, and the initial acceptance of this device decreases significantly over time hair loss cancer best order dutasteride. After treatment, both groups showed similar improvements of respiratory symptoms and had similar morbidity. Because the study treatments differed markedly between the two arms, the most meaningful measure of success is the long-term absence of recurrent pleural effusion. None of these studies, however, address the direct cost and quality-of-life assessment associated with postdischarge care of the indwelling catheter. Patients with marginal performance status should have pigtail catheter and bedside talc pleurodesis or PleurX catheter if there is failed initial talc pleurodesis or the presence of trapped lung. Patients with malignant pericardial disease may be asymptomatic or present with a number of manifestations, with pericardial effusion being the most common. Only 15% to 25% of patients with documented metastasis to the pericardium have pericardial effusion and only a small percentage of those patients will develop pericardial tamponade. Once a pericardial effusion is suspected, echocardiography should be performed to confirm its presence, to assess the hemodynamic significance of pericardial effusion, and to determine the presence of pericardial or intracardiac masses. Right atrial and ventricular collapse are the classic echocardiographic signs of cardiac tamponade, with sensitivity ranging from 38% to 60% and specificity ranging from 50% to 100%. Cytopathology and Histopathology the cytology of a pericardial effusion determines definitively its benign or malignant nature. Classic signs and symptoms of cardiac tamponade include dyspnea, orthopnea, low cardiac output (peripheral vasoconstriction, cold clammy extremities, poor capillary refill, and diaphoresis), jugular venous distention, distant heart sounds, pulsus paradoxus, and narrowed pulse pressure. An electrocardiogram may show low-voltage complexes across all monitoring leads and electrical alternans. Diagnostic Modalities Radiographic and Echocardiographic Studies Pericardial effusion should be suspected in the asymptomatic patient with cancer when an enlarged globular water-bottle pericardial silhouette is found on plain posteroanterior and lateral chest Pericardiocentesis Pericardiocentesis is the intervention of choice for patients with hemodynamic instability due to pericardial effusion as removal of as little as 50 ml of pericardial fluid can significantly improve signs and symptoms of acute cardiac tamponade. Echocardiography-guided percardiocentesis is the preferred technique as it minimizes complications and improves the success of the pericardiocentesis by delineating the size and location of the effusion relative to cardiac structures. This procedure can be performed under local anesthesia with intravenous sedation or general anesthesia. A comprehensive review of >800 patients with effusions of different etiologies who underwent subxiphoid pericardiostomy indicated an overall mortality rate of 0. Tetracycline and doxycycline have been most extensively evaluated as pericardial sclerosing agents. Successful placement of the pericardiostomy tube was achieved in 85 patients (92%). Pericardial effusion was controlled in 75 patients (88%); 10 patients (12%) did not respond to sclerosis, 8 of whom subsequently underwent surgical pericardiostomy. Successful sclerotherapy often requires multiple instillations of tetracycline or doxycycline (range, 1 to 8; median, 3); 50 patients required three or more instillations to control their effusions. Treatment-related complications (in decreasing order of frequency) included pain, catheter occlusion, fever, and atrial arrhythmias. The favorable results of this minimally invasive treatment strategy are offset by the need for repeated instillations of the sclerosing agent in order to achieve pericardial symphysis. Partial Pericardiectomy or Pericardial Window via Thoracotomy Pericardial window or pericardiectomy via thoracotomy is performed uncommonly today. However, comparative analysis indicated no difference in recurrence rates of patients treated by subxiphoid pericardiostomy compared with those undergoing transthoracic drainage. The highest success rates were noted in patients with leukemia/lymphoma and patients with breast cancer (93% and 71%, respectively). Forty-five percent of patients with other solid tumors had adequate control of their effusions as well. These authors also reported another Percutaneous Balloon-Tube Pericardiostomy Percutaneous balloon-tube pericardiostomy is an extension of the more commonly performed percutaneous tube pericardiostomy. In balloon-tube pericardiostomy, pericardiocentesis is performed as previously described but 150 to 200 ml of fluid is intentionally left in the pericardial space. Subsequently, dilatation of the needle tract is performed under fluoroscopy using a balloon catheter creating a larger pericardial opening to the subcutaneous space and mimicking surgical pericardiostomy to reduce recurrence. Ziskind and colleagues41 reported that this technique was effective in relieving pericardial effusions in 46 of 50 patients (92%). Procedurerelated complications included fever (six patients), pleural effusion requiring chest tube placement or thoracentesis (eight patients), small pneumothorax (two patients), and right ventricular injury requiring surgery (one patient) for an overall clinically significant complication rate of 18%. Of this group, 36 patients (78%) underwent initial therapeutic pericardiocentesis. Systemic chemotherapy prevented recurrence of effusion in 31 patients (67%); successful control of effusion was achieved in over two-thirds of these select individuals irrespective of whether pericardiocentesis preceded systemic therapy. Hence, the goals of intervention include relief of symptoms and prevention of recurrence if possible. Surgical (subxiphoid pericardiostomy) or medical (ultrasound-guided percutaneous tube pericardiostomy and sclerotherapy) interventions have acceptable risks and provide excellent results. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. The safety and versatility of video-thoracoscopy: a prospective analysis of 895 consecutive cases. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: a randomized study. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. A comparison of thoracoscopic talc insufflation, slurry, and mechanical abrasion pleurodesis. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Surgical management of effusive pericardial disease: influence of extent of pericardial resection on clinical course. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. Maker Malignant Ascites inciDence anD etiology Ascites is the accumulation of serous fluid in the abdominal cavity. Ascites may be found in 52% of patients at the time of cancer diagnosis,2 with up to one-third of these patients having nonmalignant etiologies for their accumulation of free peritoneal fluid. Therefore, increased net filtration can result from any of the following or a combination of (1) increased capillary permeability, (2) increased surface area, (3) increased hydraulic pressure differences, and (4) decreased oncotic pressure differences. The amount of fluid and solutes that are secreted through this layer are tightly controlled, first by the capillary endothelium, then the capillary basement membrane, followed by the interstitial stroma between the capillaries and the peritoneum, and then the mesothelial basement membrane. The capillary basement membrane is also lined with negatively charged proteoglycans, acting as a selective barrier against transit of anionic proteins. The interstitial space is a negatively charged filter of connective tissue, fibroblasts, and hyaluronic acid that is lined by the mesothelial cell basement membrane, also coated with anionic glycosaminoglycans. The peritoneal mesothelial cells also maintain a glycocalix of anionic charges, thereby forming a multilayered matrix that functions to inhibit transgression of intravascular proteins into the abdominal cavity. The total peritoneal surface area is approximately 2 m2, and fluid is continually secreted into the abdomen. At least two-thirds of peritoneal fluid reabsorbs into the open lymphatic channels of the diaphragm, leaving approximately 100 ml of fluid to lubricate and bathe the serosal surfaces. These enzymes, namely gelatinase and stromelysin-3, function to digest extracellular tissue scaffolds to allow tumor in-growth. Murine models of carcinomatosis by intraperitoneal tumor cell injection resulted in diaphragmatic and retrosternal lymph occlusion by 5 days with ascites forming soon thereafter. DiagnoSiS Comprehensive history taking combined with physical exam will diagnose ascites in most patients. If incidental low-volume ascites is found in these patients, then ascites can be aspirated and set for cytology, as can peritoneal washings. Calculated as the difference between serum and ascites albumin concentrations, values <1. If negative for malignancy, cell counts with >250 neutrophils per mm3 are suggestive of infection and Gram stain should be performed. High levels of ascitic amylase may reflect pancreatic ascites or small bowel perforation. Elevated carcinoembryonic antigen values are traditionally associated with colorectal cancer, but can also be elevated in breast, Decreased oncotic pressure Differences Chronic or advanced malignancy can result in chronic protein malnutrition. This results in a catabolic state with reduced intravascular protein, thereby creating an oncotic pressure gradient that favors fluid extravasation from the vessels into the peritoneal cavity and lack of fluid reabsorption. Intravascular volume is decreased with increasing ascites, which results in pressure-volume feedback loops that stimulate renin and aldosterone secretion. These hormones reduce urinary output and incidentally increase accumulation of ascites. Resection was not performed and the patient was treated with palliative systemic chemotherapy. Increased Ca125 levels are most suspicious for ovarian carcinoma, though they can be elevated in pancreas, lung, and breast cancers. Alphafetoprotein is another helpful serum marker, which when elevated can be indicative of hepatocellular carcinoma. Complications of diuretic use include dehydration, renal toxicity, and electrolyte imbalances that can result in cardiac arrhythmias. The goals of treatment are to provide symptomatic relief and to either maintain or improve the quality of life. Randomized controlled trials are lacking, and studies evaluating the efficacy of various treatments are difficult to extrapolate to the individual patient. Therefore, there is no standard approach to these patients and multiple medical and surgical options exist. The mainstays of treatment have been based on nonmalignant acsites and include diuretics and paracentesis. In the last few years, new systemic agents as well as regional chemotherapy combined with surgical cytoreduction have offered alternative options for palliation. In patients with carcinomatosis and/or prior surgery, there may be extensive scarring and fluid loculations, making ultrasound-guided paracentesis attractive with potentially less complications in this population. As the procedure is often required on multiple occasions,47 efficacy decreases and complication risks compound. In a study of 67 patients with ovarian, breast, and colorectal cancer, 392 paracentesis, or approximately six aspirations per patient, were required for palliation with other studies reporting mean procedure-free intervals to be 10 to 11 days. Shunting Shunting involves removal of fluid from the peritoneal cavity and returning it to the venous circulation (superior vena cava) with the goal of maintaining electrolytes and proteins, as compared to drainage procedures. The most commonly employed options include the LeVeen catheter and the Denver shunt (Denver Biomaterials Inc. Peritoneovesicular shunts were attempted; however, peritonitis and occlusion limited their utility. Management of intractable malignant ascites using the Denver peritoneovenous shunt. Various immunostimulatory agents, both specific and nonspecific, have been administered systemically and locally with varying responses.

For example hair loss women treatment 0.5 mg dutasteride purchase with visa, as discussed in Chapter 1 hair loss in men giving order genuine dutasteride online, the true diagnosis of preeclampsia is never certain by clinical criteria alone hair loss youtube buy cheap dutasteride online. Finally hair loss from stress buy cheap dutasteride on line, no matter how well the experiments are designed hair loss cure ayurvedic purchase genuine dutasteride online, certain confounders may be difficult to eliminate or circumvent, as for example treatment with magnesium sulfate or other antiseizure agents, antihypertensive medications, or parenteral fluid administration, as well as whether or not the preeclamptic woman is in active labor. Clearly, elevated blood pressure in early pregnancy is a risk marker for developing preeclampsia later; however, blood pressure values alone are a poor predictor for actually determining who will develop preeclampsia. Discriminant function analysis of the parameters predicted preeclampsia with an 88% sensitivity and specificity, and if assessment of uterine artery resistance was added, a 70% positive-predictive value at 18­26 weeks gestation was realized. With the onset of overt preeclampsia there is a shift to a low-output, high-resistance state, and intravascular volume is significantly lower than in the normal pregnant state (Chapter 15). This traditional characterization of preeclampsia as a state of decreased intravascular volume, lower cardiac output, and vasoconstriction is not observed by all investigators. A myriad of problems may contribute to the variable observations, including manipulation of volume status prior to evaluation, that can alter the pathophysiological picture present before the treatment. That said, a landmark investigation by Visser and Wallenburg85 appears to have pinpointed the reasons for these diverse findings. First, they compared a group of untreated or "virgin" preeclamptic women to a cohort of treated preeclamptics, and second, the number of subjects included ­ 87 untreated and 47 treated ­ appears to be the largest investigation using invasive technology and reported by 2014. It is also unlikely that this investigation will ever be repeated because pulmonary artery catheter monitoring is rarely used today. Instead, the wide availability of noninvasive techniques for assessment has replaced the invasive ones. Visser and Wallenburg85 carefully chose their subjects, using strict criteria and only selecting women with diastolic pressure of 100 mm Hg measured twice four hours apart, proteinuria 0. Patients with medical disorders such as chronic hypertension, cardiac or renal disease were excluded. Patients receiving intravenous fluids, antihypertensive medication, antiseizure therapy or any other type of medication were considered "treated," while those women who had not yet received any of the aforementioned therapies were the "pure (or virgin) preeclamptic" group. Finally, a group of normotensive women studied in another protocol were used for further comparison. The status of noninvasive technology, we believe, would currently preclude such studies today. Note the remarkably consistent hemodynamic parameters in the "virgin" preeclamptics, that is: a significantly decreased cardiac index, as well as the marked and significantly increased systemic vascular resistance. These findings strongly support the concept of preeclampsia being predominantly associated with low cardiac output, markedly increased systemic resistance, and an increased afterload, and suggest explanations for the variable findings of others. They reported significantly decreased cardiac output and increased systemic vascular resistance during preeclampsia, and both groups had similar hemodynamic profiles at postpartum follow-up. While the cardiovascular changes during overt preeclampsia seem clear, there are differences of opinions regarding the changes that precede clinical presentation of the disease. The general impression is that there is evidence of a vasoconstrictor state well before overt disease manifests. For instance increased sensitivity to pressor substances, increments in circulating antiangiogenic factors that affect the vasculature in a manner that opposes vasodilatation, and lower intravascular volume, precede the disease by many weeks. Although this "vasoconstricted" state with preeclampsia is more widely accepted, there is an alternate view that women destined to develop preeclampsia have an exaggeration of the normal increase in cardiac output in early pregnancy. In this scenario, championed by Easterling91 and Bosio92 and their colleagues, preeclampsia is the end result of a pregnancy originally marked by an excessive increase in cardiac output with an exaggerated compensatory decrease in systemic peripheral resistance. In this regard, they liken the preclinical phase of preeclampsia to that preceding overt essential hypertension. Eventually this autoregulation mechanism fails, afterload increases, cardiac output decreases, and hypertension becomes manifest. Thus in the combined views of Easterling91 and Bosio92 and their coworkers, preeclampsia would occur in pregnant women with exaggerated increases in cardiac output, and normal or slightly increased gestational falls in peripheral vascular resistance, but at the time the disease becomes overt there is 299 a "crossover" to a high-resistance low-output state. If this theory were to prove correct, it would be logical to try to identify women with exaggerated increases in cardiac output early in pregnancy and treat them with drugs that lower output such as beta-blockers, and indeed such a study has been done. Of 179 women, 89 had normal pregnancies, 9 developed preeclampsia, and 81 had gestational hypertension. Before disease manifestations, the women destined to develop preeclampsia had higher mean arterial pressures and cardiac output, with lower systemic resistance, albeit the latter was not significant. In this study there were no significant changes detected in either the high cardiac output state or in the reduced systemic resistance when overt signs and symptoms of preeclampsia occurred. The higher initial blood pressure in the eventual preeclamptics is consistent with findings of other investigators, but the early elevated cardiac output with normal or reduced vascular resistance had not been described previously. Of concern, there was a high drop-out rate, and only nine women developed preeclampsia, mainly mild disease ­ they were delivered at a mean of 39. Other concerns were the use of a 1 + qualitative determination to define proteinuria. Finally, the authors did not provide results for the 89 women who developed gestational hypertension, a complication of pregnancy in many women who eventually manifest essential hypertension. Given this remarkably high incidence of women with gestational hypertension in the study, viz. They too describe a high cardiac output state prior to evidence of clinical disease in the 20 women who developed preeclampsia, but here systemic vascular resistance in the latent phase was definitely normal. These investigators have suggested that the hemodynamic changes promote endothelial injury and trigger the low-output vasoconstricted state of clinical disease. In addition, information regarding administration of intravenous fluids or magnesium sulfate was not given, and they did not correct for loading conditions in assessing contractility. It is problematic, however, that this was a nonrandomized, secondary analysis that included a small number of women. More importantly, these investigators did not demonstrate prevention of preeclampsia. In addition, it is necessary to explain how this theory is compatible with overwhelming evidence that the preclinical state of preeclampsia is one marked by increased pressor responses, lower intravascular volume, and increased levels of circulating antiangiogenic proteins that impair vasodilatation. Systemic Arterial Properties in Preeclampsia Cross-Sectional Studies the earlier studies of the effects of preeclampsia on systemic arterial load have been described mostly in terms of the steady component: peripheral vasoconstriction as indicated by an increase in systemic vascular resistance. In the previous edition, we introduced more recent approaches that included assessment of the pulsatile component of arterial load and the complex interactions of the components of the cardiovascular system in the face of a low-output, high-afterload disease state. Hibbard and colleagues98 performed a cross-sectional study comparing preeclamptics, chronic hypertensives with superimposed preeclampsia, and normotensive women admitted in preterm labor. Because all women were given magnesium sulfate for either seizure prophylaxis or tocolysis, two additional control groups were included to eliminate confounding factors. One was that of normal laboring women with epidural analgesia and the second group included normotensive laboring women who were given neither epidural analgesia nor magnesium sulfate. This study confirmed that total vascular resistance, the steady component of the arterial load, was significantly elevated in both hypertensive groups, but more so in the chronic hypertensives with superimposed preeclampsia. These findings indicated the overall reservoir properties of the systemic arterial circulation to be compromised. Lower compliance (or higher stiffness) was observed for large conduit arteries as well. Thus, during the late stages of preeclampsia, both steady and pulsatile components of arterial load are elevated as compared to the normal pregnancy. Other studies have also reported similar observations regarding lower arterial compliance and increased systemic vascular resistance during late gestation in preeclamptic subjects. Interestingly, stiffness (inverse of compliance) measures changed less in the chronic hypertension group (without superimposed preeclampsia) compared with the preeclamptic group. In both studies, systemic vascular resistance was greater in the preeclamptic and chronic hypertensive groups compared with the control group. Global arterial compliance ­ or its inverse, arterial stiffness ­ has also been quantified by analyzing the central aortic pressure waveform in terms of augmentation pressure or augmentation index. Similarly, magnesium sulfate administration significantly increased arterial compliance in a cohort of 70 preeclamptic women. Longitudinal Studies Serial measurements of systemic arterial properties have been reported. In nulliparous pregnant women studied longitudinally, those destined to develop preeclampsia were noted to have elevated pulse pressures early in pregnancy, indicating higher arterial stiffness or lower compliance. The findings of these aforementioned studies suggest that the early increase in arterial compliance (or decrease in arterial stiffness) seen in normal pregnancy is absent or significantly diminished in preeclampsia. Furthermore, this aberrant compliance (stiffness) response is consistent with the views that alterations in vascular reactivity leading to a vasoconstricted state occur long before the development of preeclampsia. Using venous occlusion plethysmography, studies have shown that endothelial dysfunction persists in prior preeclamptics for as long as up to 5­6 years postpartum. Group 1 were women who had preeclampsia during their first pregnancy and group 2 were women with an uncomplicated first pregnancy. Women in the prior-preeclampsia group had higher mean and diastolic arterial pressures, higher systemic vascular resistance, reduced endothelial function (lower stress-induced increase in forearm blood flow), and a tendency towards higher arterial stiffness (increased heart-to-brachial pulse wave velocity) and higher plasma glucose level. Furthermore, the logistic regression analysis indicated that a simultaneous evaluation of multiple derived indices better discriminated between the two groups. There are a number of reports from the laboratory of Peeters and colleagues,44,117,118 which suggest that formerly preeclamptic women have endothelial abnormalities, independent of whether or not they eventually develop chronic hypertension after an index gestation complicated by preeclampsia. Those who remained normotensive and had endothelial dysfunction were termed "latent" hypertensives. Chesley suggested that remote studies should be designed to compare preeclamptics with an age- and parity-matched general population, as they may have abnormalities that predate pregnancy. The studies reviewed above may underscore preeclampsia as a marker of such abnormalities, but they cannot be used to implicate preeclampsia in their etiology. The investigators would have to have studied the women prior to pregnancy to do so, but we could locate no such studies. Although a number of studies have addressed systolic function in preeclampsia, viz. The subjects were studied at three time points: (1) prior to labor and prior to administering any antihypertensive medications, though magnesium sulfate therapy had been initiated, (2) one day postpartum when magnesium sulfate had been discontinued and subjects were still hypertensive, and (3) four weeks after delivery when the subjects were normotensive. Ten normotensive pregnant women who underwent identical protocols served as controls. As discussed before, end-systolic stress -rate corrected velocity of circumferential fiber shortening (Vcf) data were used to characterize left ventricular myocardial contractility. Proceeding from visit 1 to 3 in preeclamptics, ­Vcf points shifted leftward and upward along the nomogram, indicating decreased afterload over time without any change in left ventricular contractility. Put another way, there was decreased left ventricular performance with acute preeclampsia, but when afterload was eliminated as a confounding variable, it was obvious that contractility remained normal. From visit 1 to visit 3, data points shifted leftward and upward (arrow) but still fell on the mean contractility line, indicating decreased afterload without changes in contractility. In another investigation employing left ventricular ­ Vcf data to evaluate myocardial contractility in preeclampsia, Simmons et al. They reported similar myocardial contractility in the two groups, thereby confirming the findings of Lang et al. They reported that there were no differences in any of these systolic functional indices between women who develop preeclampsia at term and normotensive controls. In a subsequent study, however, they observed that left ventricular systolic dysfunction is evident in women who develop preterm preeclampsia before 37 weeks. They conclude that myocardial strain imaging using echocardiographic speckle tracking may help detect subclinical left ventricular dysfunction in women with preeclampsia. We emphasize, however, that one has to be cautious about this conclusion because the sample size was small (11 preeclamptics) and myocardial strain is highly dependent on afterload (myocardial stress). As normal pregnancy is a volume-loaded state with sustained mild tachycardia and hypotension, the use of these normative data from nonpregnant individuals may be questionable. Perhaps, this issue contributed to the relatively high incidence (14%) of diastolic dysfunction in the "normal" pregnancy cohort of young healthy women. These findings,67,121,122 however, do support the notion that early (preterm) preeclampsia is a more severe or possibly different form of the disease that results in greater pathophysiological changes compared to late-onset preeclampsia. When a pregnant woman lies supine, autonomic blockade with tetramethyl ammonium or spinal analgesia resulted in marked hypotension, alleviated by assuming a lateral recumbent position, while similar treatment of nonpregnant subjects had but minimal effects. These studies suggested that the predominant effect of autonomic blockade was through a loss of vasomotor tone. As noted, a reduction in afferent outflow to the resistance vasculature could explain the reduction in systemic vascular resistance. At first glance it would seem that postural differences should make comparisons between rodents and humans imprudent. However we have cited the above studies, in relation to the carefully conducted human studies by Schobel et al. These investigators, utilizing peroneal nerve microneurology techniques, also noted no differences in basal sympathetic activity when age-matched pregnant and nonpregnant women were compared. Thus, their data also suggest that pregnancy does not affect basal regulation of vascular tone by the sympathetic nervous system. There is a limited animal literature regarding autonomic nervous system function in pregnancy relating to pressuremediated changes in heart rate and blood pressure, but baroreflex regulation of heart rate involves both vagal and sympathetic nerve effects. But published results in both animals and humans give discordant results, as the baroreflex-mediated heart rate response to increasing blood pressure has been reported as enhanced, unchanged, or depressed in pregnancy. Of interest here is that in those experiments where the normal gestational difference in resting heart rate is present prior to imposed pressure steps, the reflex tachycardia is accentuated by gestational age,129,138,139 suggesting that pregnancy augments sympathetic activity to the heart in response to elevations in blood pressure. Parenthetically, we note that pregnancy had little effect on heart rate in response to decreases in blood pressure. The tachycardic response to hypotension appears unaffected by pregnancy, but this does not reflect the overall sympathetic response to hypotension. Pregnant rats show an attenuated ability to increase sympathetic nerve output in response to a hypotensive challenge. The absolute pressor response to norepinephrine was similar between groups, but the rise in pregnant women was due solely to increased cardiac output, while the pressure rise in the nonpregnant state was due to vasoconstriction. This observation is an elegant example of why examining the change in blood pressure alone is not necessarily a measure of systemic vascular reactivity. Using the identical change in blood pressure alone, one might erroneously conclude there were no changes in pregnancy. But the simultaneous recording of cardiac output permitted the correct conclusion that normal pregnancy had blunted the systemic response to norepinephrine.

Because many patients in available clinical trials have liver conditions hair loss in men over 50 dutasteride 0.5 mg buy on-line, it is unclear whether adverse effects are caused by milk thistle or by the underlying liver condition; the rates of adverse effects are often similar to placebo hair loss in men 100 buy dutasteride without a prescription. Multiple case series hair loss magnesium 0.5 mg dutasteride buy overnight delivery, retrospective analyses female hair loss in male pattern dutasteride 0.5 mg order with amex, and prospective trials of mistletoe (Viscum album hair loss from chemo order dutasteride 0.5 mg otc, Iscador) extracts in humans have been published; these studies were largely conducted in Europe and have examined patients with breast, lung, cervical, colorectal, gastric, ovarian, and pancreatic cancers, as well as renal cell carcinoma and glioma. A 1994 systematic review included 11 controlled clinical trials, not all randomized, and Reishi Clinical Studies. Caution is recommended when reishi is used in patients with bleeding disorders/coagulopathies or in those taking anticoagulants, as reishi mushroom may alter platelet aggregation and prolong bleeding time. Preliminary research using soy (Glycine max) to control hot flashes in women with breast cancer suggests that it is possibly safe,244 although the pending results of ongoing research in this area may provide more definitive safety data. Recent studies have indicated that moderate dietary soy intake (observed in most traditional Asian diets-no more than three servings daily) shows no risk and may have possible benefits to breast cancer patients, even among women with estrogen-positive breast cancers. Current epidemiologic and laboratory evidence suggests there are unlikely to be harmful effects when soy is provided in the diet consistent with amounts in a typical Asian diet. Resveratrol is a naturally occurring hydroxystilbene identified in more than 70 plant species, including nuts, grapes, pine trees, and certain vines, as well as in red wine. Although there are several observational studies that correlate the consumption of wine with a decrease in cancer or cardiovascular disease risk,217,218 high-quality human trials supporting the efficacy of resveratrol for any indication are currently lacking in the available literature. Ongoing research is examining resveratrol and a possible role in increasing longevity and how it interacts with sirtuins. Laboratory study suggests that resveratrol has antiaggregating and antithrombin activity, and may have additive effects when taken with other agents with the same actions219; thus, use of resveratrol with antiplatelets could cause increased risk of bleeding, although clinical reports of drug interactions are lacking. Some in vitro and in vivo studies suggest that resveratrol might interfere with paclitaxel. A phase 1 trial found limited toxicity with doses of turmeric (Curcuma longa, curcumin) as high as 8 g daily. A phase 2 clinical trial in pancreatic cancer found a limited response rate with 3 of 25 patients with either stable disease or a reduction in tumor size. The most common side effect with turmeric reported in humans is gastrointestinal upset, including epigastric burning, dyspepsia, nausea, and diarrhea. The study was ended early due to an interim analysis that determined that the study could not meet its expected end point of a 25% reduction in prostate cancer. Subset analyses indicated selenium supplementation was associated with increased development of diabetes mellitus. Selenium toxicity may cause gastrointestinal symptoms (nausea, vomiting, abdominal pain, diarrhea, garlic-like Vitamin A Vitamin A is comprised of retinol and its carotenoid precursors. Alltrans retinoic acid, a retinol analog, is well established as a differentiation agent in patients with acute promyelocytic leukemia. Trials have yielded variable results, suggesting no reduction in prostate cancer risk and possible increased risk of lung cancer in high-risk patients. Palliative and alternative Care 2172 Vitamin C Palliative and alternative Care / Complementary, Alternative, and Integrative Therapies nonbiologically Based therapies Nonbiologically based therapies generally fall into the categories of mind­body techniques, massage, acupuncture, and energy techniques. These techniques are generally used to support overall well-being or specific treatment-related side effects. In the 1980s, there was initial excitement over epidemiologic evidence correlating high dietary vitamin C intake with reduced rates of cancer, although use of vitamin C in observed populations may have correlated with other healthy lifestyle choices. Preclinical evidence of reduced platelet aggregation suggests that risks may outweigh potential benefits. Patients may experience scurvy symptoms after abrupt withdrawal of chronic megadoses. Two randomized controlled trials of high-dose intravenous vitamin C in cancer patients found no benefits. Mind­body modalities, including meditation, hypnosis, relaxation techniques, cognitive­behavioral therapy, biofeedback, yoga, tai chi, qigong, and guided imagery, have increasingly become part of mainstream care over the years. Techniques of stress management that may be helpful include progressive muscle relaxation,277,278 diaphragmatic breathing,279,280 guided imagery,281­283 social support,284,285 and meditation. Vitamin D Vitamin D is one of four fat-soluble vitamins and is traditionally linked with calcium metabolism and bone health. Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) are precursors to calcitriol, the active form of vitamin D. Exposing skin to natural sunlight is the most common manner by which the body produces vitamin D. Additionally, studies in cancer populations indicate a possible worse outcome in those with vitamin D deficiency. Vitamin E Vitamin E (-tocopherol) is a fat-soluble vitamin with antioxidant properties. Epidemiologic studies suggest a possible reduced breast, lung, and prostate cancer risk with intake. However, prevention trials report no reduction in risk of lung, breast, or colon cancers. Some have hypothesized that the agents may have acted as an antioxidant and thus reduced the efficacy of the radiation treatment, leading to increased recurrence rates and, ultimately, decreased survival. Several studies have evaluated the potential to protect against chemotherapy-induced peripheral neuropathy with such agents as platinums and taxanes with positive results. Numerous therapies have also been used for cancer prevention, but they have not been well studied. These include aloe, black tea, bromelain, cranberry, eucalyptus oil, ginseng, grape seed extract, lactobacillus (colon cancer risk reduction), oleander, omega-3 fatty acids/fish oil, psyllium (colon cancer risk reduction), red clover, and spirulina. Research to date suggests that massage is helpful for increasing relaxation and relieving pain, anxiety, fatigue, and distress. It is, therefore, not clear what the exact mechanisms are for the benefits of massage in an oncology setting. Despite some of the imperfections in research design, the current findings are encouraging. Massage therapy is generally safe when practiced by credentialed practitioners who have also had some training in cancer patient care. Serious adverse events are rare and tend to be associated with exotic types of massage or untrained or inexperienced practitioners. The most common form of acupuncture involves the placement of solid, sterile, stainless steel needles into various points on the body. There is good scientific evidence that acupuncture is effective for managing both postoperative and chemotherapy-related nausea and vomiting. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Host factors and cancer progression: biobehavioral signaling pathways and interventions. The benefits of psychosocial interventions for cancer patients undergoing radiotherapy. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Approach to communicating with patients about the use of nutritional supplements in cancer care. Advising patients who seek complementary and alternative medical therapies for cancer. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a populationbased case-control study. There is also good evidence that certain types of acupuncture are effective for both postoperative and chronic pain in cancer patients. Nevertheless, there is some preliminary and anecdotal evidence to suggest that acupuncture may be useful in the treatment of anxiety, depression, fatigue, constipation, loss of appetite, peripheral neuropathy, insomnia, dyspnea, and leucopenia. When performed correctly, acupuncture has been shown to be a safe, minimally invasive procedure with very few side effects. The association between dietary lignans, phytoestrogen-rich foods, and fiber intake and postmenopausal breast cancer risk: A German Case-Control Study. Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women. Beta-carotene supplementation and cancer risk: a systematic review and meta-analysis of randomized controlled trials. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a proteinbound polysaccharide preparation. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. Palliative and alternative Care 2174 Palliative and alternative Care / Complementary, Alternative, and Integrative Therapies 152. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Evaluation of oriental medicinal herbs for estrogenic and antiproliferative activities. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (iscador): a reanalysis. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. The potential diagnosis of sepsis is recognized and he is moved to the resuscitation room for further assessment and interventions. Learning point Definitions the definition of sepsis was produced by consensus in 1991. Additional definitions were produced at the time to further categorize sepsis into severe sepsis and septic shock (see Table 1. Assessment of organ dysfunction should take place early when managing any patient with suspected sepsis in order to risk stratify their condition. Measurement of blood lactate provides objective evidence of hypoperfusion and can help to identify patients with severe sepsis or septic shock rapidly. Venous and arterial lactate have been shown to be closely correlated 3 and the relative ease with which the former can be tested can help reduce the delay in identifying this group of patients.

It is generally accepted that osteoclast activation is the key step in the establishment and growth of bone metastases hair loss 6mp 0.5 mg dutasteride order with visa. Biochemical data indicate that bone resorption is of importance not only in classic "lytic" diseases such as myeloma and breast cancer hair loss in men lh buy cheapest dutasteride, but also in prostate cancer hair loss in menopause symptoms dutasteride 0.5 mg buy with visa. Chemotherapy hair loss joan rivers dutasteride 0.5 mg buy free shipping, biologically targeted agents hair loss reddit cheap dutasteride 0.5 mg overnight delivery, and endocrine treatments have direct antitumor effects, whereas agents such as the bisphosphonates and denosumab are effective by preventing host cells (primarily osteoclasts) from reacting to tumor products. In general, the choice of systemic treatment for metastatic bone disease is based on the same criteria as those used for other metastatic manifestations of the malignancy. Objectively responding patients usually gain relief of symptoms (including bone pain) and might become able to resume their previous activities. Although in general the median duration of response to endocrine therapy is around 15 months, prolonged responses to first-line hormone treatments lasting several years are not uncommon in patients with bone metastases. There have been many recent developments in cytotoxic and biologic treatments of relevance to the patient with metastatic bone disease from breast cancer. Response in bone to chemotherapy is nearly always only partial, with a median duration of response of 9 to 12 months. Chemotherapy can be more hazardous for patients with extensive bone disease, because of both poor bone marrow tolerance after replacement of functioning marrow by tumor and the effects of previous irradiation. Primary prophylaxis with hematopoietic growth factors may be required to enable chemotherapy to be administered safely. In prostate cancer, at least 80% of prostate tumors exhibit some degree of hormone responsiveness with a median duration of response of around 2 years. Until recently, treatment to extend oral Bisphosphonates the absorption of bisphosphonates from the gut is poor, variable, and dramatically inhibited by food intake. Nevertheless, oral clodronate and ibandronate have been shown in randomized trials to have useful efficacy in breast cancer. Following a single subcutaneous dose, denosumab caused rapid and sustained suppression of bone turnover in patients with multiple myeloma and patients with breast cancer. However, no differences in overall survival or investigator-reported disease progression were found between the two treatment groups in any of the studies. Denosumab does not adversely affect renal function, eliminating the need for routine monitoring of renal function. Acute-phase reactions are also less common with denosumab, but hypocalcemia is more frequent. As with intravenous bisphosphonates, the most important adverse event associated with denosumab in the oncology setting is osteonecrosis of the jaw. This occurs with similar frequency in patients treated with denosumab or zoledronic acid, affecting 0. These include radium-223, inhibitors of cathepsin K, an osteoclast-derived enzyme that is essential for the resorption of bone, and Src kinase, a key molecule in osteoclastogenesis. Radium-223 is a calcium mimetic that preferentially targets bone metastases and emits high-energy alpha particles resulting in highly localized cytotoxic effects with minimal myelosuppression. Numerous randomized trials have been conducted on dose-fractionation schedules of palliative radiotherapy. Despite that, there is still no uniform consensus on the optimal dose fractionation scheme. One of the first randomized studies on bone metastases was conducted by Radiation Therapy Oncology Group (74-02). The trial concluded that the low-dose, short-course schedules were as effective as the high-dose protracted programs. A reanalysis of the same set of data, grouping solitary and multiple bone metastases, using the end point of pain relief and taking into account of analgesic intake and retreatment, concluded that the number of radiation fractions was statistically significant related to complete combined relief (absence of pain and use of narcotics). The conclusion was that protracted dose-fractionation schedules were more effective than short-course schedules. It is currently impossible to predict whether an individual patient needs or will benefit from a bisphosphonate. Because of the logistics and cost of delivering monthly treatments to all patients with metastatic bone disease, certain empiric recommendations on who should receive treatment are needed. The recent guidelines on the management of metastatic bone disease in breast cancer from the American Society of Clinical Oncology did not recommend one bone-modifying agent (zoledronic acid, pamidronate, denosumab) over another. Denosumab or zoledronic acid is appropriate for patients with endocrine-resistant metastatic bone disease from prostate cancer,25 whereas zoledronic acid or pamidronate are recommended for multiple myeloma. The United Kingdom Bone Pain Trial Working Party randomized 765 patients with bone metastases to either an 8-Gy single fraction or a multifraction regimen (20 Gy in 5 fractions or 30 Gy in 10 fractions). There were no significant differences in the incidence of nausea, vomiting, spinal cord compression, or pathologic fracture between the two groups. The study concluded that a single 8 Gy is as safe and effective as a multifraction regimen for the palliation of metastatic bone pain for at least 12 months. The Dutch Bone Metastases Study included 1,171 patients and found no difference in pain relief or the quality of life following a single 8-Gy or 24-Gy dose in six daily radiation treatments. In the cost-utility analysis of this randomized trial, there was no difference in life expectancy or quality-adjusted life expectancy. The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule. However, two earlier meta-analyses showed no significant difference in complete and overall pain relief between single-fraction and multifraction palliative radiotherapy for bone metastases. Most patients will experience pain relief in the first 2 to 4 weeks after radiotherapy, be it single or multiple fractionations. The Radiation Therapy Oncology Group repeated the randomized study in patients with breast or prostate cancer who had one to three sites of painful bone metastases and moderate to severe pain with patient self-assessment. Grade 2 to 4 acute toxicity was more frequent in the multiple arms (17%) than in the single arm (10%) (p = 0. Complete and partial response rates were 15% and 50%, respectively, in the single-fraction arm compared with 18% and 48%, respectively, in the multiplefractions arm (p = 0. Four Norwegian and six Swedish hospitals planned to recruit 1,000 patients with painful bone metastases. Similar pain relief within the first 4 months was experienced in both groups and this was maintained throughout the 28-week follow-up. No differences were found for fatigue, global quality of life, and survival in both groups. An updated meta-analysis reporting 25 randomized trials totaling 2,818 and 2,799 randomizations in single-fraction and multiple-fraction arms revealed the overall and complete response rates were 60% and 23%, respectively, in single-fraction arm versus 61% and 24%, respectively, in multiple-fraction arms, again demonstrating equal efficacy. They concluded that a single dose was not as effective as multiple fractions for the treatment of neuropathic pain; however, it was also not significantly worse. They recommended that 20 Gy in five fractions be used as standard radiotherapy for patients with neuropathic pain. However, in patients with short survival, poor performance status, where the cost/inconvenience of multiple treatments was a factor, and in treatment centers with lengthy wait times, single fractions could be used instead. The answer most likely resides within the clinical circumstances and individual wishes of each patient. There is no doubt that in patients with short life expectancy, protracted schedules are a burden. However, in patients with a longer expected survival, such as patients with breast cancer and patients with prostate cancer with bone metastases only, other parameters need to be taken into account. Because retreatment rates are known to be higher following a single versus multiple fractions, about 25% versus 10%, respectively, patients with good performance status may wish to share in the decision-making process. A prospective randomized trial on 270 patients with painful bone metastases compared efficacy of 4-Gy or 8-Gy single doses. It is concluded that 8 Gy gives a higher probability of pain relief than 4 Gy, but that 4 Gy can be an effective alternative in situations of reduced tolerance. Another randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain consisted of single 4 Gy, 6 Gy, or 8 Gy. Toxicities include minor bone marrow suppression and gastrointestinal side effects such as nausea and vomiting in upper abdominal radiation and may be controlled with ondansetron or dexamethasone. At 1 year, 70% in the fractionated and 15% in the single-fraction group had pain control, and repeat radiation was required in 71% and 13% for the single and fractionated group, respectively. Among the three trial arms of 15 Gy in five fractions over 5 days, 8 Gy in two fractions over one day, and 12 Gy in four fractions over 2 days, the 15-Gy regimen not only provided pain relief as much as the other regimens, but also a longer survival duration in prostate cancer patients. A recent intergroup randomized trial on dose fractionations in repeat radiation for painful bone metastases in 850 patients concluded a single 8 Gy appears to be noninferior and less toxic than 20 Gy in multiple fractions with 2-month response rates in evaluable patients of 45% versus 51%, respectively (p = 0. Administration of a systemic radionuclide has the advantage of targeting all bony lesions simultaneously, and can be given as a single administration on an outpatient basis. Osteoblastic bone metastases can be detected by a technetium-99 methylenediphosphonate bone scan. Radionuclides react with bone mineral (hydroxyapatite), and the pattern of uptake mirrors that seen on the bone scan. Strontium-89 and samarium-153 are the agents most commonly used in clinical practice; phosphorus-32, rhenium-186, and tin-117 have also been used. Retention in the areas of bone metastases is greater than in the normal bone marrow, with a tumor-to-marrow ratio of 10:1. The average time to clinical response is 7 to 14 days, with a median duration of action of 18 weeks. Retreatment is possible, with an interval of 10 to 12 weeks for strontium-89 and 6 to 10 weeks for samarium-153, although a nonresponder is unlikely to respond to subsequent administration. The mechanism of pain reduction is unclear but may include radiation-induced apoptosis of lymphocyte-secreting cytokines and direct cell kill and reduction of mass effect. Treatment-related toxicity consists mainly of reversible myelosuppression, especially thrombocytopenia. The nadir is 4 to 6 weeks after injection; recovery is completed by 6 to 10 weeks, with severity related to disease burden. Bone marrow toxicity is therefore of concern with the use of systemic chemotherapy. A small percentage of patients (10% to 20%) may experience a pain flare shortly after administration. Impending or actual pathologic fracture and cord compression are also contraindications for use. The evidence for use of radionuclides has been reported in several phase 2 and 3 trials. Overall pain reduction rates for the various radionuclides are comparable and similar to localized and hemibody external beam radiotherapy, with an overall response rate of 80% and complete response rate of 20%. The "Trans Canada" study reported on 126 patients with metastatic prostate cancer randomized to strontium-89 or placebo in addition to external beam radiotherapy. Reduced lifetime requirements for radiotherapy and reduction in development of new painful bone metastases were seen. A lifetime management cost savings of $5,800 in the group receiving strontium-89 was found. Patients with a variety of primary malignancies had an 85% pain response rate, with patients with breast cancer achieving the best palliation. The recent introduction of radium-223 for advanced prostate cancer was discussed earlier. Among the radiation trials comparing single- versus multiplefractionation schemes, reirradiation rates varied from 11% to 42% following single-fraction and 0% to 24% following multiplefraction schedules. There are at least three scenarios of "failure" where reirradiation may be considered. Response to reirradiation may be different for each of these scenarios: (1) No pain relief or pain progression after initial radiotherapy, (2) partial response with initial radiotherapy and the hope to achieve further pain reduction with more radiotherapy, and (3) partial or complete response with initial radiotherapy but subsequent recurrence of pain. A total of 280 individual treatment sites were identified, of which 57 were retreated once and 8 were retreated twice. The overall response rate to initial treatment was 84% for pain relief, and at first retreatment this was 87%. Seven of the eight (88%) patients retreated a second time also achieved pain relief. A total of 17 of 23 (74%) patients responded to second radiation that used a number of single-fraction regimens, which was not significantly inferior to 31 of 34 (91%) obtained with more protracted regimens. Of 135 patients retreated, 109 patients were retreated because of pain relapsing, whereas 26 patients were reirradiated after initial nonresponse. Of the 109 patients who were reirradiated for pain relapse, 80 (74%) patients responded (complete response = 31%; partial response = 42%). Among the 26 patients who did not respond initially, there were 12 (46%) responses. The authors concluded that the lack of response to initial singlefraction radiotherapy should not deter repeat irradiation. Pathologic fractures were reported in 3 of 135 (2%) patients and spinal cord compression in 3 of 135 (2%) patients in their series. The same group reported the efficacy of the second single 4 Gy reirradiation for painful bone metastases following the previous two single fractions. The overall response rate of the 25 patients (19 responders and 6 nonresponders to the two prior single fractions) was 80%, with both complete response and partial response being 40%. No pathologic fractures or spinal cord compression were seen in any of these patients during the follow-up. Retreatment for patients with progression was successful in 70% single-fraction patients versus 57% multifraction patients. Management of the acute effects of radiotherapy requires attentive medical management that prevents expected side effects. Careful radiation treatment planning that avoids critical structures like mucosal surfaces can prevent most side effects. Patients should be reassured that the unavoidable side effects that they experience will resolve following the completion of radiotherapy. Skin reactions are usually minimal during radiotherapy for bone metastases and are limited only to the radiation portal. Nausea and vomiting, resulting from a radiation portal that includes the abdomen, will usually respond to antiemetic therapy, but ondansetron or dexamethasone also is commonly used, especially if patients have recently received emetogenic chemotherapy.

Discount dutasteride 0.5 mg without a prescription. NATURAL HAIR OIL MADE BY ME : TO FIGHT HAIR FALL DANDRUFFITCHY SCALP AND DRY HAIR.

References